Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Review article: tackling the "dyspeptic problem".

K E McColl1

  • 1University Department of Medicine & Therapeutics, Western Infirmary, Glasgow, G11 6NT, UK. k.e.l.mccoll@clinmed.gla.ac.uk

Alimentary Pharmacology & Therapeutics
|September 15, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lofepramine--a safe anti-depressant in acute hepatic porphyria?

Journal of psychopharmacology (Oxford, England)·2012
Same author

In vitro studies indicate that acid catalysed generation of N-nitrosocompounds from dietary nitrate will be maximal at the gastro-oesophageal junction and cardia.

Scandinavian journal of gastroenterology·2002
Same author

Problems associated with the clinical use of proton pump inhibitors.

Pharmacology & toxicology·2002
Same author

The role of interleukin-1 polymorphisms in the pathogenesis of gastric cancer.

Nature·2002
Same author

Helicobacter pylori and reflux disease.

Lancet (London, England)·2001
Same author

Testing for Helicobacter pylori in dyspeptic patients. Authors' strategy would leave many patients with ulcer uncured.

BMJ (Clinical research ed.)·2001
Same journal

Letter: Interpreting P-CAB Superiority for Antithrombotic Gastroprotection Beyond Acid Suppression. Authors' Reply.

Alimentary pharmacology & therapeutics·2026
Same journal

Letter: Low FODMAP Therapy in Paediatric Irritable Bowel Syndrome: Balancing Efficacy, Expectancy and Safety.

Alimentary pharmacology & therapeutics·2026
Same journal

Letter: Assessing Pruritus Efficacy With Peroxisome Proliferator-Activated Receptor Agonists in Primary Biliary Cholangitis Must Include Grading the Strength of Trial Evidence.

Alimentary pharmacology & therapeutics·2026
Same journal

Review Article: Advances in the Diagnosis of Dysplasia in Barrett's Oesophagus.

Alimentary pharmacology & therapeutics·2026
Same journal

Eosinophilic Oesophagitis Beyond the Oesophagus: High Prevalence of Chronic Rhinosinusitis-Type Symptoms and Their Impact on Symptom Severity in Swiss EoE Cohort Study Patients.

Alimentary pharmacology & therapeutics·2026
Same journal

Natural History of Recurrent Acute Pancreatitis: Implications for Interventional Trial Design.

Alimentary pharmacology & therapeutics·2026
See all related articles

Eradicating Helicobacter pylori (H. pylori) improves non-ulcer dyspepsia (NUD) symptoms and reduces risks. For NUD without H. pylori, proton pump inhibitors offer symptom relief, especially with GORD. H. pylori testing can replace endoscopy in select young patients.

Area of Science:

  • Gastroenterology
  • Internal Medicine
  • Clinical Management

Background:

  • Dyspepsia management presents clinical controversies, particularly regarding Helicobacter pylori (H. pylori) status.
  • Primary care physicians and gastroenterologists require updated information on dyspepsia treatment options.

Purpose of the Study:

  • To review H. pylori eradication in non-ulcer dyspepsia (NUD).
  • To examine therapy for NUD unrelated to H. pylori.
  • To assess H. pylori testing as an alternative to routine endoscopy for uncomplicated dyspepsia.

Main Methods:

  • Literature review of H. pylori eradication and dyspepsia treatment strategies.
  • Analysis of clinical trial data comparing H. pylori eradication, PPI therapy, and placebo.
  • Evaluation of diagnostic approaches including non-invasive H. pylori testing versus endoscopy.

Related Experiment Videos

Main Results:

  • H. pylori eradication in NUD offers superior symptom resolution, reduces ulcer and gastric cancer risks, and mitigates risks associated with long-term proton pump inhibitor (PPI) therapy.
  • For NUD patients with normal endoscopy and no H. pylori, PPI therapy is more effective than placebo for symptom control, particularly in those with symptoms or oesophageal pH-metry indicative of gastroesophageal reflux disease (GORD).
  • Non-invasive H. pylori testing is a viable option for younger dyspeptic patients lacking alarm symptoms and not using non-steroidal anti-inflammatory drugs (NSAIDs).

Conclusions:

  • H. pylori eradication is recommended for patients diagnosed with NUD.
  • PPI therapy demonstrates superiority over placebo for NUD patients without H. pylori, especially when GORD symptoms are present.
  • H. pylori testing may serve as a substitute for endoscopy in uncomplicated dyspepsia among young patients without alarm symptoms or NSAID use.